Our results are in contrast with the data published by Sorensen and colleagues showing superiority of the Ii fusion with LCMV glycoprotein as the vaccine target antigen, delivered by Ad5 in a B16 melanoma model expressing an immunodominant peptide from LCMV glycoprotein as a tumour neoantigen [21]. The gene discussed is ART4; the disease is neoplasm.